文献速递前列腺癌

Stockholm3血液检测预测活检中临床显著前列腺癌:多中心社区队列独立验证

The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-08-31

本研究在挪威和瑞典三个中心的533名45-75岁未确诊前列腺癌并计划活检的男性中独立验证Stockholm3检测。Stockholm3对GG≥2前列腺癌的AUC高于PSA联合PSA密度,以10%风险为cut-off可减少38%活检但延迟6%的GG≥2诊断。结论认为包含临床信息、蛋白水平和SNP的预测模型可减少不必要活检。

要点

  • Stockholm3对GG≥2前列腺癌的AUC为8.9(原文如此),优于PSA联合PSA密度的74.8。
  • 以Stockholm3 10%风险为cut-off可减少38%活检,但延迟6%(n=10)GG≥2诊断。
  • 以PSA密度0.1为cut-off减少35%活检,但延迟16%(n=26)GG≥2诊断。

核心结论

  • 包含临床信息、蛋白水平和SNP的预测模型在临床实践队列中得到独立验证,可减少不必要的活检,同时仅延迟少数男性的诊断。

研究设计与样本

  • 研究纳入533名45-75岁、无前列腺癌病史、计划在挪威和瑞典三个中心接受前列腺活检的男性。
  • 活检前采集血样进行Stockholm3分析,临床显著前列腺癌定义为ISUP GG≥2。

主要发现

  • 533名参与者中263名(49%)诊断为前列腺癌,其中162名GG≥2。
  • Stockholm3对GG≥2前列腺癌的AUC为8.9(95% CI 82.7-89.2),PSA联合PSA密度的AUC为74.8(95% CI 70.3-79.3)。
  • 以Stockholm3 10%风险为cut-off,节省38%活检,延迟6%(n=10)GG≥2诊断。
  • 以PSA密度0.1为cut-off,节省35%活检,延迟16%(n=26)GG≥2诊断。

关键数值与推荐

  • 临床显著前列腺癌定义为ISUP GG≥2。
  • Stockholm3 cut-off为10%的GG≥2风险。
  • PSA密度cut-off为0.1。

临床怎么用

  • 在计划前列腺活检的男性中,可考虑使用Stockholm3检测以减少不必要的活检,但需权衡少数GG≥2癌症的诊断延迟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several blood-based tests have been suggested to improve prostate cancer testing. The Stockholm3 test has been shown to reduce the number of prostate biopsies, to decrease detection of low-grade cancer and to maintain the detection rate of ISUP Gleason Group (GG) ≥ 2 cancer in a screening-by-invitation setting. We aimed to validate the performance of the Stockholm3 test in an independent, clinical practice cohort. METHODS: The study-population consisted of 533 men in ages 45-75 without previous diagnosis of prostate cancer scheduled for prostate biopsy at any of three centers in Norway and Sweden. Blood samples for Stockholm3 analysis were drawn prior to systematic prostate biopsies. Clinically significant prostate cancer was defined as any finding of ISUP Grade Group (GG) 2 or higher. We calculated area under the curve (AUC) for predicting prostate cancer at biopsy and calculated. Models including PSA and PSA-density (PSA/prostate volume) were compared to a model including also clinical information, protein levels and single nucleotide polymorphisms (SNP). RESULTS: 263 of 533 (49%) participants were diagnosed with prostate cancer. 162 men had prostate cancer with GG ≥ 2. The Stockholm3 test discriminated better for GG ≥ 2 prostate cancer than PSA in combination with PSA-density AUC 8.9 (95% CI 82.7-89.2) and AUC 74.8 (95% CI 70.3-79.3). Using a Stockholm3 cut-off of 10% risk of GG ≥ 2 cancer, 38% of the biopsy procedures were saved, however delaying diagnosis for 6% (n = 10) of men with GG ≥ 2 cancer. Using PSA-density 0.1 as cut-off for biopsy saved 35% of biopsies, delaying diagnosis for 16% (n = 26) of men with GG ≥ 2 cancer. CONCLUSION: A prediction model including clinical information, protein levels and SNPs was independently validated in a clinical practice cohort and reduces the number of un-necessary biopsies while delaying diagnosis for a limited number of men.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Möller A, Olsson H, Grönberg H, et al. The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort. Prostate Cancer Prostatic Dis. 2018. PMID: 30171228. doi:10.1038/s41391-018-0082-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。